Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature

References

• PflugfelderSCCorralesRMde PaivaCST helper cytokines in dry eye diseaseExp Eye Res201311711812524012834
   PubMed Web of Science ®Google Scholar
• Restasis^® (cyclosporine ophthalmic emulsion) [prescribing information]Irvine, CAAllergan, Inc2014
   Google Scholar
• PflugfelderSCSternMZhangSShojaeiALFA-1/ICAM-1 interaction as a therapeutic target in dry eye diseaseJ Ocul Pharmacol Ther201733151227906544
   PubMed Web of Science ®Google Scholar
• O’BrienCollumLMDry eye: diagnosis and current treatment strategiesCurr Allergy Asthma Rep20044431431915175147
   PubMed Web of Science ®Google Scholar
• BronAJTomlinsonAFoulksGNRethinking dry eye disease: a perspective on clinical implicationsOcul Surf2014122 SupplS1S3124725379
   PubMed Web of Science ®Google Scholar
• SullivanBDCrewsLAMessmerEMCorrelations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implicationsActa Ophthalmol201492216116623279964
   PubMed Web of Science ®Google Scholar
• NicholsKKNicholsJJMitchellGLThe lack of association between signs and symptoms in patients with dry eye diseaseCornea200423876277015502475
   PubMed Web of Science ®Google Scholar
• VehofJSmitt-KammingaNSNibourgSAHammondCJPredictors of discordance between symptoms and signs in dry eye diseaseOphthalmology201712428028628024826
   PubMed Web of Science ®Google Scholar
• RosenthalPBaranIJacobsDSCorneal pain without stain: is it real?Ocul Surf20097284019214350
   PubMed Web of Science ®Google Scholar
• GalorALevittRCFelixERMartinERSarantopoulosCDNeuropathic ocular pain: an important yet underevaluated feature of dry eyeEye201529330131225376119
   PubMed Web of Science ®Google Scholar
• No authors listedThe definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf200752759217508116
   PubMed Web of Science ®Google Scholar
• ScheinODMunozBTielschJMBandeen-RocheKWestSPrevalence of dry eye among the elderlyAm J Ophthalmol199712467237289402817
   PubMed Web of Science ®Google Scholar
• MossSEKleinRKleinBEPrevalence of and risk factors for dry eye syndromeArch Ophthalmol200011891264126810980773
   PubMed Web of Science ®Google Scholar
• SchiffmanRMWaltJGJacobsenGDoyleJJLebovicsGSumnerWUtility assessment among patients with dry eye diseaseOphthalmology200311071412141912867401
   PubMed Web of Science ®Google Scholar
• UchinoMSchaumbergDADry eye disease: impact on quality of life and visionCurr Ophthalmol Rep201312515723710423
   PubMedGoogle Scholar
• DogruMTsubotaKPharmacotherapy of dry eyeExpert Opin Pharmacother201112332533421214414
   PubMed Web of Science ®Google Scholar
• RidderWH3rdTomlinsonAHuangJFLiJImpaired visual performance in patients with dry eyeOcul Surf201191425521338568
   PubMed Web of Science ®Google Scholar
• MertzanisPAbetzLRajagopalanKThe relative burden of dry eye in patients’ lives: comparisons to a US normative sampleInvest Ophthalmol Vis Sci200546465015623753
   PubMed Web of Science ®Google Scholar
• MiljanovicBDanaRSullivanDASchaumbergDAImpact of dry eye syndrome on vision-related quality of lifeAm J Ophthalmol2007143340941517317388
   PubMed Web of Science ®Google Scholar
• HarmonDMurphyRDry eye market set for robust growthMarketScope2003878
   Google Scholar
• GalorAZhengDDArheartKLDry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006Cornea201231121403140722895158
   PubMed Web of Science ®Google Scholar
• LamBLZhengDDDavilaEPTrends in glaucoma medication expenditure: medical expenditure panel survey 2001–2006Arch Ophthalmol2011129101345135021670329
   PubMed Web of Science ®Google Scholar
• MartinBITurnerJAMirzaSKLeeMJComstockBADeyoRATrends in health care expenditures, utilization, and health status among US adults with spine problems, 1997–2006Spine200934192077208419675510
   PubMed Web of Science ®Google Scholar
• FoulksGNForstotSLDonshikPCClinical guidelines for management of dry eye associated with Sjögren diseaseOcul Surf201513211813225881996
   PubMed Web of Science ®Google Scholar
• ShinMSKimJILeeMSAcupuncture for treating dry eye: randomized placebo-controlled trialActa Ophthalmol2010888e328e33321070615
   PubMed Web of Science ®Google Scholar
• McGheeCNDeanSDanesh-MeyerHLocally administered ocular corticosteroids: benefits and risksDrug Saf2002251335511820911
   PubMed Web of Science ®Google Scholar
• StevensonDTauberJReisBLEfficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study GroupOphthalmology2000107596797410811092
   PubMed Web of Science ®Google Scholar
• BarberLDPflugfelderSCTauberJFoulksGNPhase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 yearsOphthalmology2005112101790179416102833
   PubMed Web of Science ®Google Scholar
• PerryHDSolomonRDonnenfeldEDEvaluation of topical cyclosporine for the treatment of dry eye diseaseArch Ophthalmol200812681046105018695097
   PubMedGoogle Scholar
• Al-SaediZHAlzhraniRMBodduSHFormulation and in vitro evaluation of cyclosporine-A inserts prepared using hydroxypropyl methylcellulose for treating dry eye diseaseJ Ocul Pharmacol Ther201632745146227294697
   PubMed Web of Science ®Google Scholar
• StevensonWChauhanSKDanaRDry eye disease: an immune-mediated ocular surface disorderArch Ophthalmol201213019010022232476
   PubMedGoogle Scholar
• SallKStevensonODMundorfTKReisBLTwo multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study GroupOphthalmology2000107463163910768324
   PubMed Web of Science ®Google Scholar
• KunertKSTisdaleASGipsonIKGoblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporineArch Ophthalmol2002120333033711879137
   PubMedGoogle Scholar
• ChenMGongLSunXA comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trialJ Ocul Pharmacol Ther201026436136620698799
   PubMed Web of Science ®Google Scholar
• DemiryayEYaylaliVCetinENYildirimCEffects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndromeEye Contact Lens201137531231521792057
   PubMed Web of Science ®Google Scholar
• KimECChoiJSJooCKA comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndromeAm J Ophthalmol2009147220621318848318
   PubMed Web of Science ®Google Scholar
• RaoSNTopical cyclosporine 0.05% for the prevention of dry eye disease progressionJ Ocul Pharmacol Ther201026215716420415623
   PubMed Web of Science ®Google Scholar
• GuzeyMKaramanSKSaticiAOzardaliISezerSBozkurtOEfficacy of topical cyclosporine a in the treatment of severe trachomatous dry eyeClin Exp Ophthalmol200937654154919702702
   PubMed Web of Science ®Google Scholar
• ByunYSRhoCRChoKChoiJANaKSJooCKCyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance studyKorean J Ophthalmol201125636937422131772
   PubMedGoogle Scholar
• RobertsCWCarnigliaPEBrazzoBGComparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eyeCornea200726780580917667613
   PubMed Web of Science ®Google Scholar
• HardtenDRBrownMJPham-VangSEvaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface diseaseCurr Med Res Opin20072392083209117822610
   PubMed Web of Science ®Google Scholar
• ParkYSongJSChoiCYYoonKCLeeHKKimHSA randomized multicenter study comparing 0.1%, 0.15%, 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eyeJ Ocul Pharmacol Ther2017332667227929721
   PubMed Web of Science ®Google Scholar
• StonecipherKGTorkildsenGLOuslerGW3rdThe IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eyeClin Ophthalmol20161088789527257373
   PubMed Web of Science ®Google Scholar
• SchiffmanRMChristiansonMDJacobsenGHirschJDReisBLReliability and validity of the ocular surface disease indexArch Ophthalmol2000118561562110815152
   PubMedGoogle Scholar
• StonecipherKPerryHDGrossRHKerneyDLThe impact of topical cyclosporine a emulsion 0.05% on the outcomes of patients with keratoconjunctivitis siccaCurr Med Res Opin20052171057106316004673
   PubMed Web of Science ®Google Scholar
• RaoSNReversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawalJ Ocul Pharmacol Ther201127660360921999340
   PubMed Web of Science ®Google Scholar
• WilsonSEPerryHDLong-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatmentOphthalmology20071141767917070588
   PubMed Web of Science ®Google Scholar
• MahFMilnerMYiuSDonnenfeldEConwayTMHollanderDAPERSIST: Physician’s evaluation of Restasis® satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewClin Ophthalmol201261971197623226002
   PubMedGoogle Scholar
• SheppardJDDonnenfeldEDHollandEJEffect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%Eye Contact Lens201440528929625083776
   PubMed Web of Science ®Google Scholar
• PrabhasawatPTesavibulNMahawongWA randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunctionCornea201231121386139323135530
   PubMed Web of Science ®Google Scholar
• HyonJYLeeYJYunPYManagement of ocular surface inflammation in Sjögren syndromeCornea2007269 Suppl 1S13S1517881909
   PubMed Web of Science ®Google Scholar
• YukselBBozdagBAcarMTopalogluEEvaluation of the effect of topical cyclosporine a with impression cytology in dry eye patientsEur J Ophthalmol201020467567920155706
   PubMed Web of Science ®Google Scholar
• Baiza-DuranLMedrano-PalafoxJHernandez-QuintelaELozano-AlcazarJAlaníz-de laO JFA comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndromeBr J Ophthalmol201094101312131520679084
   PubMed Web of Science ®Google Scholar
• AmesPGalorACyclosporine ophthalmic emulsion for the treatment of dry eye: a review of the clinical evidenceClin Investig (Lond)201553267285
   Google Scholar
• DastjerdiMHHamrahPDanaRHigh-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimenCornea200928101091109619770713
   PubMed Web of Science ®Google Scholar
• SuMYPerryHDBarsamAThe effect of decreasing the dosage of cyclosporine a 0.05% on dry eye disease after 1 year of twice-daily therapyCornea201130101098110421407074
   PubMed Web of Science ®Google Scholar
• PrabhasawatPTesavibulNKarnchanachetaneeCKasemsonSEfficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eyeJ Ocul Pharmacol Ther201329337237723289903
   PubMed Web of Science ®Google Scholar
• GurdalCGencISaracOTopical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expressionCurr Eye Res201035977177720795858
   PubMed Web of Science ®Google Scholar
• KiangETesavibulNYeeRKellawayJPrzepiorkaDThe use of topical cyclosporine a in ocular graft-versus-host-diseaseBone Marrow Transplant1998222145151
   Web of Science ®Google Scholar
• LelliGJJrMuschDCGuptaAFarjoQANairusTMMianSIOphthalmic cyclosporine use in ocular GVHDCornea200625663563817077652
   PubMed Web of Science ®Google Scholar
• RaoSNRaoRDEfficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host diseaseCornea200625667467817077659
   PubMed Web of Science ®Google Scholar
• WangYOgawaYDogruMOcular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host diseaseBone Marrow Transplant200841329330217982500
   PubMed Web of Science ®Google Scholar
• MaltaJBSoongHKShteinRMTreatment of ocular graft-versus-host disease with topical cyclosporine 0.05%Cornea201029121392139620847658
   PubMed Web of Science ®Google Scholar
• BoyntonGERaoofDNiziolLMHussainMMianSIProspective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantationCornea201534772573225850708
   PubMed Web of Science ®Google Scholar
• HoehnMEKellySRWilsonMWWaltonRCCyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in childrenPediatr Blood Cancer2013607E35E3723335290
   PubMed Web of Science ®Google Scholar
• FoulksGNWhat is dry eye and what does it mean to the contact lens wearer?Eye Contact Lens2003291 SupplS96S10012772742
   PubMedGoogle Scholar
• HomMMUse of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patientsEye Contact Lens200632210911116538135
   PubMedGoogle Scholar
• WillenCMMcGwinGLiuBOwsleyCRosenstielCEfficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyesEye Contact Lens2008341434518180683
   PubMed Web of Science ®Google Scholar
• JabburNSSakataniKO’BrienTPSurvey of complications and recommendations for management in dissatisfied patients seeking a consultation after refractive surgeryJ Cataract Refract Surg20043091867187415342048
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDSolomonKPerryHDThe effect of hinge position on corneal sensation and dry eye after LASIKOphthalmology200311051023102912750107
   PubMed Web of Science ®Google Scholar
• SalibGMMcDonaldMBSmolekMSafety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusisJ Cataract Refract Surg200632577277816765793
   PubMed Web of Science ®Google Scholar
• TorricelliAASanthiagoMRWilsonSETopical cyclosporine a treatment in corneal refractive surgery and patients with dry eyeJ Refract Surg201430855856425325897
   PubMed Web of Science ®Google Scholar
• LeeHSJangJYLeeSHImSKYoonKCClinical effectiveness of topical cyclosporine a 0.05% after laser epithelial keratomileusisCornea2013327e150e15523665647
   PubMed Web of Science ®Google Scholar
• UrseaRPurcellTLTanBUThe effect of cyclosporine A (Restasis) on recovery of visual acuity following LASIKJ Refract Surg20082447347618494339
   PubMed Web of Science ®Google Scholar
• HessertDTanzerDBrunstetterTKauppSMurdochDMirzaoffMTopical cyclosporine a for postoperative photorefractive keratectomy and laser in situ keratomileusisJ Cataract Refract Surg201339453954723415779
   PubMed Web of Science ®Google Scholar
• GoyalSHamrahPUnderstanding neuropathic corneal pain-gaps and current therapeutic approachesSemin Ophthalmol2016311–2597026959131
   PubMed Web of Science ®Google Scholar
• CraneAMFeuerWFelixEREvidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked painBr J Ophthalmol Epub2017118
   Web of Science ®Google Scholar
• LeonardiAVan SettenGAmraneMEfficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trialEur J Ophthalmol201626428729627055414
   PubMed Web of Science ®Google Scholar
• KimHCsakyKGGilgerBCPreclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host diseaseInvest Ophthalmol Vis Sci200546265566215671296
   PubMed Web of Science ®Google Scholar
• KapoorYChauhanAOphthalmic delivery of cyclosporine A from brij-97 microemulsion and surfactant-laden p-HEMA hydrogelsInt J Pharm20083611–222222918577433
   PubMed Web of Science ®Google Scholar
• GuptaCChauhanAOphthalmic delivery of cyclosporine a by punctal plugsJ Control Release20111501707621074586
   PubMed Web of Science ®Google Scholar